Evan Seigerman, an analyst from BMO Capital, maintained the Hold rating on Bristol-Myers Squibb (BMY – Research Report). The associated price target remains the same with $61.00.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Evan Seigerman has given his Hold rating due to a combination of factors related to Bristol-Myers Squibb’s current and future projections. The company’s guidance for 2025 was below market expectations, which has led to a recalibration of investor outlooks. This adjustment could create a more favorable investment landscape, despite the initial disappointment.
Seigerman recognizes several upcoming catalysts that may positively impact the company’s stock, such as trials for ADEPT-2, ARISE, Krazati 1L NSCLC, and data from Camyos’s nHCM. Additionally, he expresses growing confidence in specific growth assets like Breyanzi and Camzyos, which are beginning to show promising trends. Despite these potential upsides, the recommendation remains a Hold as the stock is deemed fairly valued with stable cash flows from existing businesses.
In another report released today, Bank of America Securities also reiterated a Hold rating on the stock with a $63.00 price target.